DL
REGN icon

Delta Lloyd’s Regeneron Pharmaceuticals REGN Stock Holding History

Delta Lloyd’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5,913
Closed -$2.38M – 569
2016
Q3 		$2.38M Hold
5,913
– – 0.07% 212
2016
Q2 		$2.06M Hold
5,913
– – 0.07% 213
2016
Q1 		$2.13M Sell
5,913
-385
-6% -$159K 0.07% 205
2015
Q4 		$3.42M Buy
6,298
+600
+11% +$325K 0.12% 137
2015
Q3 		$2.65M Buy
5,698
+831
+17% +$446K 0.08% 189
2015
Q2 		$2.48M Buy
4,867
+1,090
+29% +$532K 0.08% 196
2015
Q1 		$1.71M Buy
3,777
+11
+0.3% +$4.66K 0.05% 201
2014
Q4 		$1.54M Buy
3,766
+472
+14% +$186K 0.05% 219
2014
Q3 		$1.19M Hold
3,294
– – 0.01% 238
2014
Q2 		$930K Buy
3,294
+520
+19% +$154K 0.03% 270
2014
Q1 		$833K Buy
2,774
+28
+1% +$8.63K 0.03% 265
2013
Q4 		$756K Sell
2,746
-20,109
-88% -$5.78M 0.03% 274
2013
Q3 		$7.15M Buy
22,855
+21,087
+1,193% +$5.55M 0.27% 80
2013
Q2 		$398K Buy
+1,768
New +$412K 0.02% 361

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Delta Lloyd's REGN Position: Q4 2016 in Review

Delta Lloyd sold out of Regeneron Pharmaceuticals (REGN) in Q4 2016, closing a stake of 5,913 shares — an estimated $2.38M sold.

Delta Lloyd first reported a position in REGN in Q2 2013 and held it in 14 quarters. The position peaked at $7.15M in Q3 2013. 576 funds tracked by Wall St. Rank hold REGN as of Q4 2016.

  • Delta Lloyd reported no remaining Regeneron Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Delta Lloyd sold 5,913 Regeneron Pharmaceuticals shares in Q4 2016, an estimated $2.38M.
  • Delta Lloyd first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Delta Lloyd's Regeneron Pharmaceuticals position peaked at $7.15M in Q3 2013.
  • 576 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2016.

Based on Delta Lloyd's 13F filing for Q4 2016, filed 2 Feb 2017.